HOME > TOP STORIES
TOP STORIES
-
BUSINESS 70% of Major Products Fall Victim to Off-Year Drug Re-Pricing: Jiho Tally
March 10, 2021
-
BUSINESS Top-Tier Drug Makers Face 2-4% Cuts, Mid-Sized Firms 6-8% in Japan’s First Off-Year Re-Pricing: Tally
March 9, 2021
-
BUSINESS Top-3 Generic Makers Hit with Average 9.8% Price Cut in Off-Year Revision: Jiho Tally
March 9, 2021
-
BUSINESS Takeda Aims for Mid-Teens Annual Growth in Japan Oncology Biz: Exec
March 8, 2021
-
REGULATORY MHLW Presents Views on “Pharma Industry Vision 2021” to LDP’s Project Team
March 8, 2021
-
REGULATORY Japan Confirms 1st Case of Anaphylaxis from COVID-19 Vaccination
March 8, 2021
-
REGULATORY Japan to Review Moderna Vaccine with Top Priority, May OK Possible: Minister
March 8, 2021
-
BUSINESS Takeda Submits NDA for Moderna Vaccine in Japan
March 5, 2021
-
REGULATORY Pfizer, Bayer to Pull Plug on “G1” Products with High Generic Erosions
March 5, 2021
-
REGULATORY MHLW Announces New Drug Prices for 1st Off-Year Revision in April
March 5, 2021
-
ORGANIZATION Fast-Track Approval System, New Pricing Rules Needed for Therapeutic Apps: DTx Consortium
March 5, 2021
-
BUSINESS Nichi-Iko Chief Apologizes for GMP Violations, but Draws Clear Distinction from Kobayashi Kako Case
March 4, 2021
-
BUSINESS AbbVie Japan to Boost Immunology Reps as It Gears Up for Rinvoq/Skyrizi Label Expansions
March 3, 2021
-
REGULATORY Nichi-Iko Ordered to Suspend Biz over Sloppy Manufacturing
March 3, 2021
-
REGULATORY Woman Dies 3 Days after COVID-19 Vaccine Shot, but Link Indeterminable
March 3, 2021
-
BUSINESS Iwasaki to Bow Out as Chief of Takeda’s Japan Pharma Biz Unit
March 3, 2021
-
BUSINESS Kyowa Kirin Poised to Speed Up Growth with 5 Strategic Launches, Eyes Blockbuster Potential in Eczema Med
March 2, 2021
-
REGULATORY Nichi-Iko to Get Business Suspension Order on March 3
March 2, 2021
-
BUSINESS Takeda to Offload 4 Diabetes Meds in Japan to Teijin for 133 Billion Yen
March 1, 2021
-
REGULATORY Govt to Deliver 1st COVID-19 Vaccine Dose for 3.7 Million HCPs in April: Minister
March 1, 2021
ページ
On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
